Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

10.71 -0.23 (-2.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Fall Off A Cliff
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
NeuroPace's Return On Capital Employed Overview
Via Benzinga
Recap: NeuroPace Q1 Earnings
Via Benzinga
Looking Into NeuroPace's Return On Capital Employed
Via Benzinga
NeuroPace Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Alpha Tau Medical Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) rose 62.4% to $3.15 in pre-market trading after falling 11% on Monday. Tivic Health Systems inked a pact to make its products available on... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
NeuroPace to Participate in Upcoming Investor Conferences
From NeuroPace, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2023
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
NeuroPace Reports Second Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Inducement Grants Under Listing Rule 5635(c)(4) of The Nasdaq Stock Market
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report Second Quarter 2023 Financial Results on August 8, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces CEO Transition
From NeuroPace, Inc.
Via GlobeNewswire
People Are Lining Up For Elon Musk's Neuralink Brain Implant — Here's How You Can Invest In Brain Technology Startups
Via Benzinga
NeuroPace Announces Addition of Kelley Nicholas as Vice President, Sales
To focus on commercial growth, including expanding adoption and driving higher utilization of NeuroPace’s RNS System 
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Report First Quarter 2023 Financial Results on May 4, 2023
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace to Present at the 22nd Annual Needham Virtual Healthcare Conference
From NeuroPace, Inc.
Via GlobeNewswire
Dow Jumps Over 300 Points; S&P 500 Rises 1.5%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Friday. The Dow traded up 1.03% to 33,343.73 while the NASDAQ rose 1.92% to 11,682.86. The S&P... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. 
Via Benzinga
Nasdaq Up 150 Points; Crude Oil Rises 1%
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday. The Dow traded up 0.59% to 33,197.08 while the NASDAQ rose 1.32% to 11,614.60. The S&P... 
Via Benzinga
NeuroPace Reports Fourth Quarter & Full Year 2022 Financial Results
From NeuroPace, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.